Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
|Articles|May 1, 2001
Postmenopausal estrogen therapy and ovarian cancer
Small patient numbers, weak associations, plus the mixed story in the observational studies complicate accurate interpretation of the latest epidemiologic study on ERT.
Advertisement
Advertisement
Related to this article
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.
Jessica Shepherd, MD, MBA, FACOG, joins Missed & Dismissed to discuss why perimenopause is overlooked and how disparities shape who gets care.
Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
Matthew Nudy, MD, on estrogen and the cardiovascular system
3
Mind, Body, & the Pause: Menopause, brain fog, and screening gaps, with Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG
4
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
5